Readmission following methotrexate treatment for tubal pregnancy.

Yossi BartNoam RegevUria ShaniBracha CohenFayrooz YossefNadine MargiehNir Kugelman

Published in: International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics (2024)

Readmission following methotrexate treatment for tubal pregnancy was independently associated with previous pelvic inflammatory disease and pretreatment serum hCG levels. The latter was also associated with surgical intervention rate.

Keyphrases

randomized controlled trial
high dose
preterm birth
oxidative stress
low dose
combination therapy
replacement therapy